SCHEMBL669436

SCHEMBL669436

Cc1n[nH]cc1C=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20525190 0.80 CDK4 (0.36)
SCHEMBL1767963 0.76
SCHEMBL18517969 0.73
SCHEMBL9132195 0.73
SCHEMBL12336079 0.73
SCHEMBL3451735 0.73 MEN1 (0.33)
SCHEMBL1702959 0.71
SCHEMBL12264347 0.71
SCHEMBL27950172 0.71
SCHEMBL8407888 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103524417-B One group of 3-methyl-4-formyl pyrazole compound QINGDAO AGRICULTURAL UNIVERSITY (CN) 2016-04-27 CN claimed
CN-103524417-A 3-methyl-4-formyl pyrazol compounds UNIV QINGDAO AGRICULTURAL 2014-01-22 CN claimed
CN-119931076-B Method for synthesizing metal organic framework material by aqueous phase one-pot method JINAN UNIVERSITY (CN) 2026-05-26 CN disclosed
WO-2026087634-A1 TREM2 AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2026-04-30 WO disclosed
EP-4725554-A2 COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES Yuhan Corporation (KR) 2026-04-15 EP disclosed
US-20260078130-A1 NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF SIRONAX LTD (KY) 2026-03-19 US disclosed
US-12577226-B2 Compounds for treating Huntington's disease PTC THERAPEUTICS, INC. (US) 2026-03-17 US disclosed
US-12415803-B2 Fused imidazopyridines as reversible inhibitors of Brutons Tyrosine Kinase (BTK) MERCK PATENT GMBH (DE) 2025-09-16 US disclosed
US-RE50528-E1 Compounds and compositions for modulating EGFR mutant kinase activities YUHAN CORPORATION (KR) 2025-08-12 US disclosed
EP-4590674-A1 NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd (KY) 2025-07-30 EP disclosed
EP-4584269-A1 PYRAZOLO[1,5-A]PYRIDINE AND IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS FGFR3 INHIBITORS FOR THE TREATMENT OF CANCER Eli Lilly and Company (US) 2025-07-16 EP disclosed
WO-2000075139-A2 BENZOTHIAZINONE AND BENZOXAZINONE COMPOUNDS BASF AKTIENGESELLSCHAFT (DE) 2000-12-14 WO disclosed
WO-2000066567-A1 PYRIMIDINONE COMPOUNDS SMITHKLINE BEECHAM PLC (GB) 2000-11-09 WO disclosed
EP-1028955-A1 PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SmithKline Beecham p.l.c. (GB) 2000-08-23 EP disclosed
WO-2000043395-A1 SUBSTITUTED PORPHYRINS NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (US) 2000-07-27 WO disclosed
WO-1999024420-A1 PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SMITHKLINE BEECHAM PLC (GB) 1999-05-20 WO disclosed
EP-0900197-A1 BETA-THIOPROPIONYL-AMINOACID DERIVATIVES AND THEIR USE AS BETA-LACTAMASE INHIBITORS SMITHKLINE BEECHAM PLC (GB) 1999-03-10 EP disclosed
WO-1997030027-A1 BETA-THIOPROPIONYL-AMINOACID DERIVATIVES AND THEIR USE AS BETA-LACTAMASE INHIBITORS SMITHKLINE BEECHAM PLC (GB) 1997-08-21 WO disclosed
EP-0605524-A1 ANTIBACTERIAL, ANTIMYCOPLASMAL COMPOUNDS RELATED TO MUPIROCIN SMITHKLINE BEECHAM PLC (GB) 1994-07-13 EP disclosed
EP-0154132-A1 6-Alkylidene penems, their preparation and use, and intermediates BEECHAM GROUP PLC (GB) 1985-09-11 EP disclosed